This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_AML_EXALLC for full statistics.
Acute myeloid leukaemia
C3_AML
acute myeloid leukemia: Acute myeloid leukemia (AML) is a group of neoplasms arising from precursor cells committed to the myeloid cell-line differentiation. All of them are characterized by clonal expansion of myeloid blasts. AML manifests by fever, pallor, anemia, hemorrhages and recurrent infections.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditions
|
351 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
351 |
4. Check minimum number of eventsNone |
351 |
5. Include endpoints |
351 |
6. Filter based on genotype QC (FinnGen only) |
351 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF8
Similar endpoints
↥List of similar endpoints to
Acute myeloid leukaemia
based on the number of shared cases.
Similar with more cases:
- Acute myeloid leukaemia, helper endpoint
- Acute myeloid leukaemia, excluding all cancers (controls excluding all cancers)
- Acute myeloid leukaemia and myelodysplastic syndromes
- Acute myeloid leukaemia and myelodysplastic syndromes, excluding all cancers (controls excluding all cancers)
- Any event in cancer register
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 351 | 146 | 205 |
| Unadjusted period prevalence (%) | 0.07 | 0.05 | 0.09 |
| Median age at first event (years) | 65.59 | 57.96 | 71.03 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 359
- Matched controls
- 3587
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
+∞
323.0
313
*
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
+∞
295.1
241
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
113.2
245.3
260
81
XW000
NOMESCO Finland
Bone marrow biopsy
78.2
181.6
202
58
WW500
NOMESCO Finland
Blood transfusion
29.0
101.6
142
79
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
50.0
100.6
121
36
127
Kela drug reimbursment
Transplant complication
82.5
75.3
83
13
A05AA02
ATC
ursodeoxycholic acid; oral
94.2
69.2
75
10
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
201.3
65.4
66
*
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
64.6
60
*
A04AA01
ATC
ondansetron; systemic, rectal
13.1
56.5
106
111
J05AB11
ATC
valaciclovir; oral
8.2
49.8
126
222
L03AA02
ATC
filgrastim; parenteral
22.8
49.2
72
39
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
11.5
46.0
91
103
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.3
40.4
124
276
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
9.6
38.2
83
109
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.3
38.1
116
253
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
16.1
36.9
61
45
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
394.9
36.7
36
*
R50.9
ICD-10 Finland
Fever, unspecified
5.6
36.6
126
318
J02AC03
ATC
voriconazole; systemic
382.6
35.6
35
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
26.8
35.5
49
21
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
12.9
33.5
61
56
L04AD01
ATC
ciclosporin; systemic
22.7
31.8
46
23
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
+∞
31.7
30
*
J01MA12
ATC
levofloxacin; systemic
4.5
31.5
136
426
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
42.2
30.9
38
10
WW200
NOMESCO Finland
Immunization
15.5
30.1
50
37
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
87.6
29.3
32
*
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
19.9
29.2
44
25
D64.9
ICD-10 Finland
Anaemia, unspecified
5.3
28.5
97
233
D70.89
ICD-10 Finland
Neutropenic splenomegaly
21.9
28.1
41
21
ZX120
NOMESCO Finland
Intravenous
5.8
27.9
87
188
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
9.1
27.6
60
77
9891/3-C42.1
ICD-O-3
Acute monocytic leukemia of bone marrow
+∞
27.4
26
*
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
81.3
27.2
30
*
M04AA01
ATC
allopurinol; systemic
4.4
25.4
105
306
C92.4
ICD-10 Finland
Acute promyelocytic leukaemia [PML]
+∞
25.3
24
*
C92.5
ICD-10 Finland
Acute myelomonocytic leukaemia
+∞
25.3
24
*
A41.9
ICD-10 Finland
Sepsis, unspecified
9.3
25.3
54
67
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
7.7
25.1
61
93
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
267.8
25.0
25
*
J02AC04
ATC
posaconazole; systemic
+∞
24.2
23
*
1DB06
NOMESCO Finland
NA
+∞
24.2
23
*
L01BB02
ATC
mercaptopurine; oral
33.7
24.1
31
10
121
Kela drug reimbursment
Severe hypofunction of sexual glands
16.0
24.0
39
27
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
10.0
24.0
49
56
J02AC01
ATC
fluconazole; systemic
3.3
23.5
159
693
A41.1
ICD-10 Finland
Sepsis due to other specified staphylococcus
58.1
23.4
27
5
C95.9
ICD-10 Finland
Leukaemia, unspecified
244.9
22.9
23
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.0
22.2
209
1129
2050A
ICD-9 Finland
Myeloid leukaemia, Acute
+∞
22.1
21
*
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
22.1
21
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
9.2
22.0
47
58
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
233.6
21.8
22
*
9873/3-C42.1
ICD-O-3
Acute myeloid leukemia without maturation of bone marrow
+∞
21.0
20
*
N02AA05
ATC
oxycodone; systemic
3.7
19.3
95
315
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.5
19.3
104
372
ZX112
NOMESCO Finland
Subcutaneous
11.3
19.1
36
35
2AX04
NOMESCO Finland
NA
+∞
18.9
18
*
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
18.9
18
*
TGC00
NOMESCO Finland
Bronchial lavation
11.6
18.9
35
33
B73
ICPC
Leukaemia
200.0
18.7
19
*
D46.2
ICD-10 Finland
Refractory anaemia with excess of blasts [RAEB]
200.0
18.7
19
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
32.0
18.6
24
8
L04AA06
ATC
mycophenolic acid; systemic
16.5
18.3
29
19
Z51.5
ICD-10 Finland
Palliative care
5.9
18.2
53
103
JN4BD
NOMESCO Finland
Extensive body CT
4.0
17.0
73
213
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
94.5
16.7
18
*
TPH00
NOMESCO Finland
Phlebotomy
177.9
16.6
17
*
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
6.9
16.2
41
66
TPX10
NOMESCO Finland
Implantation of vascular injection port
8.5
16.0
35
45
1BC07
NOMESCO Finland
NA
+∞
15.7
15
*
ZX121
NOMESCO Finland
Central venous catheter
89.0
15.7
17
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
40.0
15.5
19
5
WW409
NOMESCO Finland
Other aferesis
47.2
15.2
18
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.8
15.1
52
122
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
59.3
14.9
17
*
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
7.7
14.7
34
48
J05AB01
ATC
aciclovir; systemic
3.0
14.6
98
400
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.6
14.1
136
690
ZXM00
NOMESCO Finland
Intraoperative use of ultrasonographic imaging
18.5
14.0
21
12
B25.9
ICD-10 Finland
Cytomegaloviral disease, unspecified
+∞
13.6
13
*
9866/3-C42.1
ICD-O-3
Acute promyelocytic leukemia, t(15;17)(q22;q11-12) of bone marrow
+∞
13.6
13
*
C93.0
ICD-10 Finland
Acute monoblastic/monocytic leukaemia
+∞
13.6
13
*
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
35.6
13.6
17
5
L01XX05
ATC
hydroxycarbamide; oral
13.6
13.6
23
18
J01MA14
ATC
moxifloxacin; systemic
3.8
13.3
59
176
A40.8
ICD-10 Finland
Other streptococcal sepsis
17.6
13.1
20
12
L04AA01
ATC
[U] ciclosporin; systemic
17.6
13.1
20
12
H02AB09
ATC
hydrocortisone; systemic
10.2
12.9
25
26
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
12.8
143
774
WD515
NOMESCO Finland
Demanding therapy of malignancy with enzyme inhibitors and similar treatments
72.5
12.7
14
*
9920/3-C42.1
ICD-O-3
Therapy-related myeloid neoplasm of bone marrow
+∞
12.6
12
*
1DB07
NOMESCO Finland
NA
+∞
12.6
12
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.6
11.7
101
474
9874/3-C42.1
ICD-O-3
Acute myeloid leukemia with maturation of bone marrow
+∞
11.5
11
*
H02AB04
ATC
methylprednisolone; systemic
2.9
11.3
74
292
N05BA06
ATC
lorazepam; systemic, sublingual
5.0
11.3
36
78
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
11.7
11.2
20
18
PH1AE
NOMESCO Finland
Ultrasound examination of upper extremity veins
11.1
10.9
20
19
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
11.1
10.9
20
19
L04AD02
ATC
tacrolimus; systemic (calcineurin inhibitors)
22.3
10.8
15
7
WW304
NOMESCO Finland
Transfer of stem cells from registered domestic donator
+∞
10.5
10
*
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
6.3
10.3
27
46
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
9.9
97
482
R4110
NOMESCO Finland
Physiotherapy
2.2
9.6
115
624
TAB00
NOMESCO Finland
Lumbar puncture
4.9
9.5
30
65
5BA08
NOMESCO Finland
NA
22.4
9.4
13
6
9867/3-C42.1
ICD-O-3
Acute myelomonocytic leukemia, NOS, of bone marrow
+∞
9.4
9
*
A41.8
ICD-10 Finland
Other specified sepsis
7.6
9.4
21
29
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.4
9.1
88
431
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
11.1
8.9
16
15
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.0
8.6
141
869
212
Kela drug reimbursment
Gout
5.3
8.5
25
50
A98
ICPC
Health maint/preventive medicine
0.5
8.4
232
2833
Z85.6
ICD-10 Finland
Personal history of leukaemia
+∞
8.4
8
*
306
Kela drug reimbursment
Erythropoietin and darbepoetin
34.2
8.1
10
*
C90.0
ICD-10 Finland
Multiple myeloma
13.4
7.9
13
10
JN1CG
NOMESCO Finland
Extensive MRI examination of upper part of abdomen with high intensity magnet
6.6
7.8
19
30
ZX090
NOMESCO Finland
Other technic of radiotherapy
5.8
7.8
21
38
ZX108
NOMESCO Finland
Inhalation
15.5
7.8
12
8
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
46.0
7.7
9
*
RS221
NOMESCO Finland
NA
11.2
7.4
13
12
9895/3-C42.1
ICD-O-3
Acute myeloid leukemia with myelodysplasia-related changes of bone marrow
+∞
7.3
7
*
B37.7
ICD-10 Finland
Candidal sepsis
+∞
7.3
7
*
20500
ICD-8 Finland
Myeloid leukaemia, Acute
+∞
7.3
7
*
D89.89
ICD-10 Finland
Other specified disorders involving the immune mechanism, not elsewhere classified
+∞
7.3
7
*
2AX05
NOMESCO Finland
NA
+∞
7.3
7
*
GD1AD
NOMESCO Finland
Thorax CT examination
4.6
7.3
24
55
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.6
7.2
31
91
D64.8
ICD-10 Finland
Other specified anaemias
8.2
7.2
15
19
SPAT1088
SPAT
Blood transfusion
20.5
7.2
10
5
ED1AA
NOMESCO Finland
Mandipular X-ray examination
20.5
7.2
10
5
A07AA09
ATC
vancomycin; oral
8.9
6.6
13
15
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.6
6.6
46
189
D70.82
ICD-10 Finland
Drug-induced neutropenia
6.4
6.5
16
26
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
3.1
6.4
33
113
2AA01
NOMESCO Finland
NA
+∞
6.3
6
*
C92.7
ICD-10 Finland
Other myeloid leukaemia
+∞
6.3
6
*
C92.3
ICD-10 Finland
Myeloid sarcoma
+∞
6.3
6
*
G61.0
ICD-10 Finland
Guillain-Barré syndrome
+∞
6.3
6
*
D46.3
ICD-10 Finland
Refractory anemia with excess of blasts with transformation
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
112
55
29.44
154.08
7.0
1.7
—
—
—
0
0
93
51
24.45
120.98
1.4
1.4
—
—
—
0
0
88
46
25.20
116.69
1.5
1.6
101.9
96.3
u/ml
0.18
24
11
82
44
24.01
107.21
12.0
8.1
731.1
625.1
iu/ml
—
15
9
85
51
21.67
105.64
1.4
1.4
243.6
258.1
u/ml
0.08
54
30
77
39
25.01
103.02
4.1
5.7
711.2
875.4
u/ml
—
6
5
74
66
13.94
73.28
4.5
1.8
—
—
—
0
0
74
68
13.52
71.88
4.2
1.8
—
—
—
0
0
63
49
15.45
67.47
4.5
1.7
—
—
—
0
0
58
0
+∞
62.38
1.0
0.0
—
—
—
0
0
69
81
10.36
56.16
1.5
1.8
—
—
—
0
0
41
19
24.30
55.93
1.9
1.2
—
—
—
0
0
43
29
16.76
49.34
3.0
1.6
—
—
—
0
0
49
45
12.49
47.00
9.5
3.8
0.8
1.4
%
0.57
43
35
45
36
14.19
46.96
2.7
1.7
—
—
—
0
0
38
22
19.25
46.94
1.3
1.0
—
—
—
0
0
78
131
7.37
46.75
1.7
2.3
1.6
1.6
g/l
0.22
67
115
39
26
16.75
44.92
5.1
1.8
—
—
—
0
0
39
29
15.00
42.32
5.1
1.8
—
—
—
0
0
136
425
4.59
40.36
14.5
3.8
0.8
0.8
mmol/l
0.10
129
395
32
19
18.43
38.90
5.7
1.6
359.1
508.5
e6/l
—
15
8
27
11
26.51
38.30
2.3
1.5
—
—
—
0
0
45
49
10.39
38.25
2.0
1.8
—
—
—
0
0
84
207
5.02
32.96
4.0
1.5
—
—
—
0
0
30
24
13.57
31.01
1.9
1.8
—
—
—
0
0
35
6
64.50
30.71
1.3
1.0
—
—
—
0
0
30
25
13.03
30.25
4.9
2.3
—
—
—
0
0
26
18
15.52
29.08
7.2
4.1
—
—
—
0
0
35
40
9.61
28.53
2.0
1.7
—
—
—
0
0
30
28
11.62
28.14
9.9
2.9
39.7
58.8
%
2.02
22
19
28
24
12.59
27.71
1.2
1.5
—
—
—
0
0
158
685
3.38
27.21
11.0
2.9
315.0
6945.6
umol/l
3.19
152
578
24
18
14.24
25.63
1.4
1.8
—
—
—
0
0
24
18
14.24
25.63
1.4
1.8
—
—
—
0
0
22
15
15.58
24.70
1.6
1.2
—
—
—
0
0
47
94
5.62
23.05
3.3
3.1
—
—
—
0
0
27
31
9.35
21.82
6.1
1.7
—
—
—
0
0
27
31
9.35
21.82
6.1
1.7
—
—
—
0
0
27
31
9.35
21.82
6.1
1.7
—
—
—
0
0
44
87
5.64
21.81
2.5
1.3
—
—
—
0
0
23
21
11.65
21.77
1.3
1.1
—
—
—
0
0
28
36
8.37
20.71
2.2
1.9
—
—
—
0
0
36
62
6.36
20.53
1.3
2.1
40.1
13.2
mg/l
0.97
31
57
19
15
13.33
19.58
1.1
1.0
—
—
—
0
0
18
13
14.54
19.49
7.9
1.8
—
—
—
0
0
18
13
14.54
19.49
7.9
1.8
—
—
—
0
0
116
498
2.99
19.19
4.4
1.9
—
—
—
0
0
90
337
3.25
18.83
3.1
1.9
—
—
—
0
0
209
1227
2.74
18.76
25.4
6.2
33.1
26.7
%
7.90
203
1136
18
14
13.50
18.68
7.9
1.8
—
—
—
0
0
128
590
2.84
18.46
3.2
1.8
4.4
1.3
mg/l
2.27
115
452
29
45
6.93
18.21
2.2
1.8
—
—
—
0
0
16
11
15.19
17.72
1.1
1.4
—
—
—
0
0
19
18
11.10
17.47
7.7
1.7
—
—
—
0
0
19
18
11.10
17.47
7.7
1.7
—
—
—
0
0
19
18
11.10
17.47
7.7
1.7
—
—
—
0
0
19
18
11.10
17.47
7.7
1.7
—
—
—
0
0
87
336
3.11
17.14
3.0
1.8
—
—
—
0
0
196
1208
2.41
14.55
23.6
6.0
47.0
58.1
%
16.58
190
1126
13
11
12.23
12.70
2.7
1.5
—
—
—
0
0
16
5
33.41
12.68
2.0
1.6
—
—
—
0
0
16
20
8.33
11.97
2.8
1.4
—
—
—
0
0
16
20
8.33
11.97
2.8
1.4
—
—
—
0
0
21
36
6.14
11.94
7.1
2.0
33.2
33.1
pg
0.01
21
36
120
642
2.32
11.79
15.6
2.4
—
—
—
0
0
24
49
5.18
11.38
1.6
1.4
—
—
—
0
0
14
17
8.54
10.68
3.0
1.3
—
—
—
0
0
14
17
8.54
10.68
3.0
1.3
—
—
—
0
0
15
8
19.51
10.35
10.2
1.5
—
—
—
0
0
212
1481
2.09
10.09
57.1
9.5
2.9
4.2
e9/l
2.55
202
1293
182
1206
2.06
9.96
24.6
4.2
—
—
—
0
0
21
46
4.79
9.19
2.6
1.2
3.8
3.9
mmol/l
0.26
21
41
10
11
9.33
8.12
2.9
1.9
1224.6
955.5
u/ml
—
10
11
13
20
6.71
8.12
3.1
1.8
—
—
—
0
0
193
1368
1.91
8.10
21.6
6.6
1.2
1.2
mmol/l
0.22
167
1136
129
809
1.94
7.78
6.7
3.1
30.0
33.2
u/l
0.95
124
772
179
1254
1.87
7.64
18.7
6.2
1.2
1.2
mmol/l
1.28
172
1115
16
33
5.03
7.48
5.0
1.5
—
—
—
0
0
170
1184
1.85
7.28
20.1
4.5
32.4
34.8
g/l
5.38
164
1092
20
51
4.10
7.26
8.2
3.7
41.6
59.3
%
3.78
20
51
16
34
4.88
7.23
5.0
1.5
—
—
—
0
0
16
34
4.88
7.23
5.0
1.5
—
—
—
0
0
16
34
4.88
7.23
5.0
1.5
—
—
—
0
0
16
34
4.88
7.23
5.0
1.5
—
—
—
0
0
10
5
20.52
7.17
1.2
1.2
—
—
—
0
0
233
2771
0.53
7.02
88.2
23.4
3.7
4.4
e12/l
34.75
227
2680
16
35
4.74
7.00
5.0
1.5
—
—
—
0
0
233
2770
0.53
6.98
88.2
23.4
162.0
242.2
e9/l
21.60
227
2691
23
67
3.60
6.97
1.6
1.4
—
—
—
0
0
23
67
3.60
6.97
1.6
1.4
—
—
—
0
0
21
58
3.79
6.86
4.2
1.4
—
—
—
0
0
197
2434
0.57
6.26
4.7
5.0
2.6
2.6
mmol/l
0.06
184
2192
74
417
1.98
5.91
1.5
2.4
2.0
2.3
g/l
4.30
69
380
52
257
2.20
5.86
1.9
2.4
0.2
0.2
g/l
0.28
46
239
22
70
3.29
5.85
2.3
1.4
—
—
—
0
0
10
9
11.39
5.83
6.2
5.2
197.5
219.3
u/l
—
10
9
190
2348
0.58
5.68
50.9
15.0
79.4
77.0
ml/min/173m2
0.70
161
1934
9
7
13.15
5.61
1.4
1.4
—
—
—
0
0
9
7
13.15
5.61
1.8
1.3
—
—
—
0
0
20
62
3.36
5.54
1.2
1.2
—
—
—
0
0
70
396
1.96
5.51
1.6
2.5
38.7
22.1
%
5.52
54
342
149
1061
1.70
5.47
4.3
2.7
860.9
137.1
ug/l
3.65
140
970
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
24
84
2.99
5.47
3.7
3.0
0.3
0.3
u/ml
0.00
12
45
186
2302
0.59
5.46
5.2
6.2
40.1
40.7
mmol/mol
0.39
171
2101
5
0
+∞
5.22
7.6
0.0
—
—
—
0
0
193
2347
0.61
4.99
4.4
4.5
1.3
1.4
mmol/l
5.85
179
2112
36
165
2.32
4.85
1.6
1.4
—
—
—
0
0
227
2646
0.60
4.81
43.6
10.7
29.0
25.0
u/l
3.20
220
2528
23
87
2.76
4.59
1.1
4.0
—
1.4
—
0
9
198
2374
0.62
4.56
5.6
4.7
6.0
6.1
mmol/l
0.04
182
2124
10
21
4.87
4.56
1.1
1.2
—
—
—
0
0
15
44
3.52
4.52
1.1
1.1
—
—
—
0
0
30
131
2.41
4.50
7.3
1.9
—
—
—
0
0
9
12
7.66
4.38
3.0
2.0
—
—
—
0
0
8
9
9.06
4.30
1.4
1.1
—
—
—
0
0
9
13
7.07
4.18
3.0
1.9
—
—
—
0
0
83
537
1.71
4.17
4.8
4.0
96.3
308.0
ng/l
1.11
74
439
17
58
3.03
4.07
3.2
1.4
10.5
27.0
iu/l
2.12
12
52
9
14
6.56
4.01
1.1
1.0
—
—
—
0
0
191
2282
0.64
3.99
5.5
4.5
1.9
2.0
mu/l
0.09
178
2020
200
2364
0.64
3.95
5.0
4.5
4.3
4.5
mmol/l
1.19
188
2144
229
2618
0.64
3.72
57.8
18.8
138.7
139.6
mmol/l
5.34
224
2536
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
8
12
6.79
3.69
1.4
1.2
—
—
—
0
0
9
16
5.74
3.68
3.0
1.9
—
—
—
0
0
36
188
2.02
3.54
9.4
6.0
24.8
24.4
mmol/l
0.28
36
177
6
6
10.14
3.51
2.7
1.5
—
—
—
0
0
103
733
1.57
3.50
2.3
2.1
2.7
3.3
mg/l
2.23
83
631
120
889
1.53
3.40
6.1
3.2
2.3
2.3
mmol/l
2.49
108
760
7
10
7.12
3.38
1.3
1.1
—
—
—
0
0
6
7
8.69
3.27
1.2
1.0
—
—
—
0
0
25
117
2.22
3.25
3.2
1.7
—
—
—
0
0
85
602
1.54
2.90
1.9
1.8
1322.4
1183.2
nmol/l
0.59
76
445
19
83
2.36
2.89
1.2
1.4
—
—
—
0
0
6
9
6.76
2.88
1.3
1.0
—
—
—
0
0
196
2268
0.69
2.87
5.4
4.0
1.6
1.3
mmol/l
5.60
183
2035
41
241
1.79
2.86
2.0
2.2
410.4
364.8
nmol/l
0.89
41
222
9
23
3.99
2.79
5.1
1.8
—
—
—
0
0
29
510
0.53
2.79
1.3
1.2
0.8
1.1
u/ml
—
6
142
23
113
2.11
2.68
1.4
2.8
—
—
—
0
0
45
279
1.70
2.62
5.0
4.6
1.4
1.7
mmol/l
0.15
35
221
5
7
7.23
2.55
1.2
1.0
—
—
—
0
0
5
7
7.23
2.55
1.2
1.0
—
—
—
0
0
6
11
5.53
2.55
1.0
1.5
100.5
23.8
u/l
—
6
11
156
1854
0.71
2.48
5.0
3.8
14.8
14.9
pmol/l
0.28
144
1639
126
1005
1.40
2.28
5.4
3.3
—
—
—
0
0
76
1008
0.69
2.22
4.5
5.2
2.3
3.0
ug/l
0.64
68
877
49
325
1.59
2.22
8.6
7.0
1.3
1.1
mmol/l
0.09
39
256
41
260
1.65
2.22
9.4
7.1
99.5
119.9
g/l
7.80
41
254
64
453
1.50
2.18
5.2
3.0
3.2
2.1
e6/l
0.32
37
269
230
2545
0.72
2.17
70.0
16.2
36.7
26.0
mg/l
3.75
218
2061
57
794
0.66
2.14
4.3
4.7
20.1
21.5
%
0.24
28
398
107
840
1.39
2.10
4.2
2.4
48.1
55.6
u/l
1.74
97
777
17
83
2.10
2.04
1.5
3.3
0.0
0.0
g/l
0.00
17
78
11
44
2.55
2.03
1.2
1.5
—
—
—
0
0
137
1126
1.36
2.01
2.2
2.1
85.6
93.0
pmol/l
1.26
100
578
17
85
2.05
1.93
1.5
3.2
0.0
0.0
g/l
0.00
17
78
9
196
0.45
1.91
2.2
2.2
—
—
—
0
0
12
52
2.35
1.90
1.0
1.1
—
—
—
0
0
198
2220
0.75
1.87
62.1
17.3
33.2
39.2
%
11.47
124
1506
29
176
1.71
1.86
3.2
1.7
—
—
—
0
0
38
560
0.64
1.85
3.0
3.1
0.9
0.9
ug/l
0.06
24
382
17
87
2.00
1.83
1.3
1.2
—
—
—
0
0
17
88
1.98
1.78
1.3
1.2
—
—
—
0
0
9
36
2.54
1.75
4.7
4.1
—
—
—
0
0
9
36
2.54
1.75
1.1
1.7
—
—
—
0
0
17
90
1.93
1.68
1.5
3.1
0.0
0.0
g/l
0.00
17
83
8
175
0.44
1.62
2.4
2.0
—
—
—
0
0
5
14
3.61
1.62
2.0
2.9
25.6
26.4
umol/l
—
5
14
5
14
3.61
1.62
1.6
5.5
110.6
95.5
%
—
5
14
6
20
3.03
1.58
1.0
1.3
—
—
—
0
0
6
20
3.03
1.58
1.0
1.3
—
—
—
0
0
6
21
2.89
1.51
1.0
1.2
—
—
—
0
0
6
21
2.89
1.51
1.0
1.2
—
—
—
0
0
6
21
2.89
1.51
1.0
1.1
—
—
—
0
0
6
21
2.89
1.51
1.0
1.2
—
—
—
0
0
7
28
2.53
1.46
1.0
1.1
—
—
—
0
0
62
474
1.37
1.41
5.2
2.9
1.5
1.1
e6/l
0.15
36
287
13
67
1.98
1.40
1.4
1.3
—
—
—
0
0
9
41
2.23
1.38
1.3
1.1
—
—
—
0
0
122
1415
0.79
1.31
3.6
2.8
—
—
—
0
0
6
25
2.42
1.25
1.0
1.1
—
—
—
0
0
6
25
2.42
1.25
1.0
1.1
—
—
—
0
0
21
132
1.63
1.23
6.6
4.3
25.0
24.9
mmol/l
0.05
21
126
94
780
1.28
1.22
5.5
3.3
0.3
0.5
e6/l
0.46
73
601
5
19
2.65
1.22
1.2
1.1
—
—
—
0
0
8
148
0.53
1.06
3.1
1.6
—
—
—
0
0
20
131
1.56
1.02
1.4
1.3
—
—
—
0
0
0
32
0.00
0.95
0.0
1.5
—
—
—
0
0
11
62
1.80
0.95
2.0
2.1
109.8
129.0
g/l
1.55
11
44
6
30
2.02
0.87
2.0
1.3
—
—
—
0
0
189
1746
1.18
0.80
6.6
4.8
320.1
4079.8
e6/l
—
7
40
14
208
0.66
0.76
5.0
2.9
62.2
62.4
ml/min/173m2
—
6
91
0
28
0.00
0.76
0.0
1.5
—
—
—
0
0
0
28
0.00
0.76
0.0
1.5
—
—
—
0
0
0
28
0.00
0.76
0.0
1.5
—
—
—
0
0
17
116
1.49
0.75
3.4
4.2
1.7
1.5
%
0.45
17
108
17
118
1.46
0.70
4.0
2.8
29.1
41.8
u/ml
0.43
17
112
7
43
1.64
0.67
7.4
2.9
25.7
33.3
u/ml
—
7
43
8
124
0.64
0.55
3.1
2.9
11.1
1512.4
u/ml
—
8
106
12
82
1.48
0.55
8.4
5.5
1.2
1.6
mg/l
1.60
12
73
14
99
1.43
0.55
6.6
3.5
3.5
4.0
mmol/l
3.06
14
88
91
822
1.14
0.49
3.3
2.2
136.4
284.4
u/l
1.89
85
767
36
422
0.84
0.43
20.1
27.5
1.1
1.4
inr
—
7
54
5
32
1.57
0.42
1.0
1.4
—
—
—
0
0
10
70
1.44
0.42
1.1
2.1
—
—
—
0
0
8
58
1.39
0.42
1.3
1.2
—
10.3
—
0
11
5
33
1.52
0.41
1.2
1.3
368.6
330.6
u/l
—
5
33
35
403
0.85
0.35
1.2
1.2
14.0
34.5
iu/ml
3.24
12
142
6
46
1.31
0.33
1.2
1.2
—
—
—
0
0
57
514
1.13
0.33
2.7
3.1
2.4
2.5
mmol/l
0.36
49
440
24
284
0.83
0.33
1.9
1.4
—
—
—
0
0
117
1240
0.92
0.31
5.6
5.5
0.0
0.0
estimate
0.00
22
235
33
375
0.87
0.29
1.2
1.3
1.0
13.4
u/ml
—
7
150
111
1054
1.08
0.24
2.7
2.3
74.5
75.7
nmol/l
0.17
100
920
120
1255
0.93
0.22
3.9
4.1
0.0
0.0
estimate
0.00
22
235
5
40
1.25
0.22
1.2
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
341.6
—
0
5
0
10
0.00
0.21
0.0
1.0
—
8.8
—
0
10
8
102
0.78
0.21
2.3
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
6
50
1.20
0.20
1.8
1.4
—
—
—
0
0
65
610
1.08
0.19
1.6
1.8
464.4
11332443.0
pmol/l
0.50
54
503
117
1126
1.06
0.17
3.7
4.0
32.7
45.2
ng/l
0.85
90
816
5
66
0.75
0.17
1.0
1.4
—
—
—
0
0
94
974
0.95
0.13
3.7
4.3
—
—
—
0
0
121
1238
0.97
0.09
3.8
4.1
0.0
0.0
estimate
0.00
24
245
153
1556
0.97
0.08
4.9
3.2
66.6
50.9
u/l
1.10
143
1434
17
156
1.09
0.08
6.2
7.2
24.5
24.5
mmol/l
0.01
17
156
39
372
1.05
0.08
1.5
1.5
—
—
—
0
0
9
85
1.06
0.07
1.7
1.8
—
—
—
0
0
34
325
1.05
0.06
3.0
4.7
26.4
32.2
%
2.42
27
201
27
276
0.98
0.00
8.3
3.7
—
—
—
0
0
69
688
1.00
0.00
3.5
4.4
0.0
0.0
estimate
0.00
22
233
33
331
1.00
0.00
14.8
7.7
—
—
—
0
0
192
1916
1.00
0.00
5.0
4.1
26.0
13.4
mm/h
8.87
180
1738
30
305
0.98
0.00
3.6
4.0
3.3
49.4
ug/l
1.12
25
259
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
6
64
0.94
0.00
1.7
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_AML – Acute myeloid leukaemia
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).